Trials / Terminated
TerminatedNCT03841448
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete \>1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). These participants are at high risk for progression of kidney disease, which can result in end-stage renal failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC. |
| DRUG | Cemdisiran | Cemdisiran was administered by SC injection. |
Timeline
- Start date
- 2019-09-30
- Primary completion
- 2022-03-17
- Completion
- 2023-06-27
- First posted
- 2019-02-15
- Last updated
- 2024-08-09
- Results posted
- 2023-12-08
Locations
17 sites across 9 countries: Canada, France, Malaysia, Philippines, Singapore, Spain, Sweden, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03841448. Inclusion in this directory is not an endorsement.